注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品包括巴托利单抗,主要用于免疫性血小板减少症、甲状腺相关性眼病、重症肌无力、视神经脊髓炎谱系疾病等;以及特那西普,主要用于干眼病。此外,该公司还研究和开发肿瘤免疫产品管线,包括内部开发的新一代肿瘤免疫资产,针对治疗免疫沙漠型、免疫排斥型及炎症型肿瘤。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Jingsong Wang | 57 | 2016 | Founder, Chairman & CEO |
Jon Marc Wigginton | - | 2020 | Member of Scientific Advisory Board |
Robert A. Kramer | - | 2016 | Member of Scientific Advisory Board |
Peter F. Moesta | - | - | Member of Scientific Advisory Board & Chief CMC Advisor |
Frank Grosveld | - | 2016 | Member of Scientific Advisory Board |
Yiping Rong | 45 | 2022 | Chief Scientific Officer & Executive Director |
Xiaoping Ye | 59 | 2020 | Independent Non-Executive Director |
Ka Chi Yau | 64 | 2021 | Independent Non-Executive Director |
Robert Irwin Kamen | 79 | 2016 | Independent Non-Executive Director & Member of Scientific Advisory Board |
Zhigang Tian | - | 2020 | Member of Scientific Advisory Board |
Jon Marc Wigginton | 61 | 2020 | Member of Scientific Advisory Board |
Albert R. Collinson | 65 | 2023 | Independent Non-Executive Director |
Weiwei Chen | 57 | 2020 | Senior Business Adviser & Non-Executive Director |
Alexander A. Zukiwski | 66 | 2022 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核